Torisel Action Date Extended To July 5
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA will use extension to examine new tumor evaluation information submitted by Wyeth.
You may also be interested in...
Wyeth’s Torisel To Launch In July Following FDA Approval
Renal cell carcinoma treatment will compete with Bayer/Onyx’s Nexavar and Pfizer’s Sutent.
Wyeth’s Torisel To Launch In July Following FDA Approval
Renal cell carcinoma treatment will compete with Bayer/Onyx’s Nexavar and Pfizer’s Sutent.
Wyeth Pharmaceuticals U.S. President Geno Germano: An Interview With “The Pink Sheet” DAILY
Exec discusses Wyeth's selling model and how the firm is planning for potential launches this year of products like Pristiq and Torisel.